Reviva Pharmaceuticals is a clinical-stage biopharmaceutical company that aims to discover, develop and commercialize next-generation therapeutics for diseases within the CNS, respiratory, cardiovascular, metabolic, and inflammatory areas. Lead product RP5063 is currently in Phase III for the treatment of schizophrenia, completed Phase I for bipolar disorder and other mental disorders, as well as several respiratory diseases while RP1208 is in pre-clinical development for depression and obesity. The company is headquartered in Cupertino, California.